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Abstract
Background: Vitamin D supplementation for fracture prevention is widespread despite conflicting interpretation of 
relevant randomised controlled trial (RCT) evidence. This study summarises quantitatively the current evidence from 
RCTs and observational studies regarding vitamin D, parathyroid hormone (PTH) and hip fracture risk.
Methods: We undertook separate meta-analyses of RCTs examining vitamin D supplementation and hip fracture, and 
observational studies of serum vitamin D status (25-hydroxyvitamin D (25(OH)D) level), PTH and hip fracture. Results 
from RCTs were combined using the reported hazard ratios/relative risks (RR). Results from case-control studies were 
combined using the ratio of 25(OH)D and PTH measurements of hip fracture cases compared with controls. Original 
published studies of vitamin D, PTH and hip fracture were identified through PubMed and Web of Science databases, 
searches of reference lists and forward citations of key papers.
Results: The seven eligible RCTs identified showed no significant difference in hip fracture risk in those randomised to 
cholecalciferol or ergocalciferol supplementation versus placebo/control (RR = 1.13[95%CI 0.98-1.29]; 801 cases), with 
no significant difference between trials of <800 IU/day and ≥800 IU/day. The 17 identified case-control studies found 
33% lower serum 25(OH)D levels in cases compared to controls, based on 1903 cases. This difference was significantly 
greater in studies with population-based compared to hospital-based controls (χ2
1 (heterogeneity) = 51.02, p < 0.001) 
and significant heterogeneity was present overall (χ2
16 (heterogeneity) = 137.9, p < 0.001). Serum PTH levels in hip 
fracture cases did not differ significantly from controls, based on ten case-control studies with 905 cases (χ2
9 
(heterogeneity) = 149.68, p < 0.001).
Conclusions: Neither higher nor lower dose vitamin D supplementation prevented hip fracture. Randomised and 
observational data on vitamin D and hip fracture appear to differ. The reason for this is unclear; one possible 
explanation is uncontrolled confounding in observational studies. Post-fracture PTH levels are unrelated to hip fracture 
risk.
Background
Vitamin D supplementation is widely considered to be an
important therapy for the prevention of fracture and use
for this purpose is both widespread and recommended,
with and without calcium [1-3]. Previous meta-analyses
of randomised controlled trials found either no signifi-
cant effect of vitamin D on fracture risk [4,5] or have been
interpreted as indicating that vitamin D doses of ≥700-
800 IU/day [6] or "received doses" of ≥400 IU/day [7] are
required to prevent fracture. Notably, however, key
higher dose trials in these latter meta-analyses were trials
of placebo versus combined vitamin D plus calcium sup-
* Correspondence: jeffrey.lai@anu.edu.au
1 National Centre for Epidemiology and Population Health, The Australian 
National University, Canberra, ACT, 0200, Australia
Full list of author information is available at the end of the articleLai et al. BMC Public Health 2010, 10:331
http://www.biomedcentral.com/1471-2458/10/331
Page 2 of 17
plementation [8-11] and calcium supplementation is now
known to have an independent protective effect on frac-
ture [12]. This raises questions on the efficacy and neces-
sity of vitamin D supplementation independent of
calcium.
Hip fracture is the most serious outcome of osteoporo-
sis and an important and increasing health problem. It is
common amongst older individuals and is associated
with significant morbidity and mortality. In 2000, there
were estimated 1.6 million hip fractures worldwide [13]
and mortality in the year following hip fracture is esti-
mated at 20-30% [14]. The social and economic burden of
hip fractures worldwide is expected to increase signifi-
cantly over the next 50 years due to ageing populations,
especially within developing countries [15-17]. Identifica-
tion of interventions that can prevent hip fractures
remains a key research priority and vitamin D is an
appealing therapy to fulfil this role.
In addition to the randomised data, the opinions and
practices of researchers, clinicians and communities are
likely to be influenced by factors including observational
studies and the longstanding knowledge of the relation-
ship between vitamin D and osteomalacia. In the face of
the continuing uncertainty and the need for firm evi-
dence to guide practice, an up to date and broader quanti-
tative examination of the evidence regarding vitamin D
and fracture is warranted. Shrier et al suggest that the
advantages of examining different levels of evidence by
including observational studies with RCTs in meta-analy-
ses may outweigh the disadvantages [18]. This study is
designed to be the first summary of the available serolog-
ical evidence on both vitamin D and PTH in relation to
hip fracture, and the first meta-analysis of case-control
studies on this topic.
Methods
Search Strategy and Eligibility
We applied the inclusion and exclusion criteria below to
studies identified through searches of the PubMed and
Web of Science databases, additional articles identified
from the reference lists of sourced papers, hand searching
of relevant journals and forward citations searches of key
papers, to include publications up to April 2009.
Studies were included if they were published, English
language, original research articles and were one of the
following.
a) A randomised controlled trial including a minimum
of 100 participants combined across vitamin D treatment
(cholecalciferol or ergocalciferol) and control groups,
with at least one radiologically confirmed hip fracture in
each group; b) A case-control study including a minimum
of 50 cases of hip fracture together with specified control
participants and post-fracture serum 25(OH)D (the usual
blood measure of vitamin D status) and/or PTH levels.
Studies must have reported sufficient data to allow the
calculation of a mean and standard deviation for serologi-
cal measurements; or c) A cohort study recording con-
firmed incident hip fracture and the relationship to
serum 25(OH)D levels ascertained from prospectively
collected blood samples.
Exclusion criteria included randomised controlled
studies that used vitamin D treatment combined with
other therapies such that the individual effect of vitamin
D could not be established [8-11]; studies that included
hip fractures as a component of all fractures but without
individual counts; and studies published as abstracts only.
Although only studies from English-language publica-
tions were included, PubMed encompasses abstracts
from non-English publications. This revealed only one
relevant non-English language study [19] and this
abstract provided similar results to the other studies that
were included.
Data were independently extracted by three reviewers
(JL, EB, RL) and discrepant results reconciled through
arbitration. Two of the reviewers (EB and RL) are
researchers and specialist public health physicians and
one (JL) has qualifications in statistics. Adjusted results
were used where possible. JL conducted the quality
assessment.
Quality Assessment of included studies
R a n d o m i s e d  c o n t r o l l e d  t r i a l s  w e r e  a s s e s s e d  f o r  q u a l i t y
based upon allocation concealment, blinding of interven-
tions, and the total loss to follow up. Lower quality stud-
ies were those considered to be inadequate in any of the
above areas (no allocation concealment, no blinding of
interventions or >25% loss to follow up) including studies
where the description presented was not clear. We inves-
tigated heterogeneity between lower and higher quality
studies.
For observational studies, the quality assessment was
based upon adjustment for confounding (none = 1 point,
age and sex = 2 points, age and sex plus other possible
confounders = 3 points), the selection of cases and con-
trols over a comparable time period (1 point for same
period or season), and the adequate description of patient
characteristics (1 point for inclusion of characteristics
such as residential status, sunshine exposure, calcium
intake and medical history). These broad criteria were
taken from the list of most commonly used measures in a
review of quality assessments of observational studies
[20]. Adjustment for confounding was weighted more
heavily as it was considered the best proxy for study qual-
ity. Based upon the number of points scored out of a
maximum of 5, each study was given a quality rating from
1 (lowest) to 5 (highest). We investigated heterogeneity
between lower quality studies (1 and 2) compared to
higher quality studies (3, 4 and 5).Lai et al. BMC Public Health 2010, 10:331
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Statistical analysis and presentation of results
For the randomised controlled trials we tabulated the
measure of association for hip fracture comparing vita-
min D treatment and control groups. Some studies pro-
vided the hazard ratio from a Cox Proportional Hazards
model. For studies where this was not available, we calcu-
lated the relative risk from raw data [21,22]. To check the
validity of directly comparing these measures of associa-
tion, we calculated the relative risk (RR) (from the raw
data) for all studies and performed a sensitivity analysis
using a standard t-test with unequal variances to compare
the results obtained by this method to those using the
adjusted hazard ratio. This revealed that the treatment
effects using both methods were statistically equal (p =
0.99) and as such the adjusted results were used where
possible. Outcomes were analysed on an intention-to-
treat basis. We examined heterogeneity of results accord-
ing to the type and dose of vitamin D used, mode of
administration, use of placebo, reported levels of compli-
ance, and according to whether or not participants were
community dwelling or institutionalized, using the
Cochrane Q statistic [23,24] with the p-value obtained
from a chi-squared distribution with n-1 degrees of free-
dom. Overall heterogeneity between individual studies
was investigated using the Cochrane Q statistic in addi-
tion to the H and I2 statistics with the p-value obtained
from a standard normal distribution. The I2 statistic is a
transformation of the H statistic and represents 'the pro-
portion of variance attributable to heterogeneity'. Further
details on its calculation are outlined in Higgins et al [25].
Cut-offs for heterogeneity were taken at p = 0.05. We
tested for publication bias using funnel plots and asym-
metry determined using Egger's linear regression
approach with the p-value obtained from a t-distribution
with n-2 degrees of freedom [26].
Most case-control studies reported the mean and stan-
dard deviation of serum 25(OH)D levels directly. How-
ever, in studies where participants were stratified
according to gender or season, we obtained the combined
standard deviation from the usual ANOVA sum-of-
squares breakdown.
Within case-control studies, 25(OH)D and PTH mea-
surements of hip fracture patients and controls were
compared using a ratio estimator of the respective means.
To account for the positively skewed distribution com-
mon in serological measurements a logarithmic transfor-
mation of the data was used to better approximate
normality. As most studies reported only the arithmetic
mean and standard error, it was necessary to estimate the
geometric mean and standard error on the log trans-
formed scale using asymptotic Taylor series approxima-
tions. Details of the methodology used are outlined in
Higgins et al [27].
Results were summarised across studies using the
weighted average of the study-specific log ratios, with
each individual weight inversely proportional to its esti-
mated variance. Graphically log ratios are represented as
black squares with areas proportional to their weights
indicating the amount of statistical information for each
particular study. The corresponding confidence interval
(CI) is drawn as a line extending from the estimated log
ratio.
We decided a priori to test for heterogeneity according
to the use of population- or hospital- based controls.
Hospital-based controls were defined as hospital inpa-
tients or outpatients identified for inclusion in the study
either during or as a direct result of diagnostic or medical
treatment. All other controls drawn from home-based or
housing for the elderly populations were taken as popula-
tion-based controls. We further tested for heterogeneity
due to geographical location, mean age of controls, time
between fracture and serum collection, and type of vita-
min D assay.
All analyses were undertaken with the R computing
package (version 2.5.1; 2007, available at: http://
www.cran.r-project.org) [28].
Major results from cohort studies were presented as
reported in the original studies. A meta-analysis of esti-
mates was not possible due to the different cut points for
serum 25(OH)D from each study.
Results
Randomised controlled trials
A total of seven eligible randomised controlled trials
recording hip fractures was identified (see Figure 1)
[21,22,29-33]. Six studies were vitamin D versus placebo
or "no treatment" trials [22,29-33], and one was a factorial
design investigating vitamin D versus placebo and vita-
min D and calcium versus calcium alone [21]. The same
study was a secondary fracture prevention study that
selected participants based upon a previous fracture his-
tory. Table 1 summarises the studies including study pop-
ulations, vitamin D dose and type, mode of
administration, change in 25(OH)D levels and the relative
risk or hazard ratio reported in the study paper.
The pooled analysis of these studies (Figure 2) included
424 and 377 hip fractures in the vitamin D and control
groups respectively. The weighted RR was 1.13 (95%CI,
0.98-1.29). There was no evidence of heterogeneity (χ2
7 =
4.44, p = 0.73 and H = 1, I2 = 0%, p = 1), including in rela-
tion to geographical location. All studies reported ade-
quate allocation concealment; one study did not use
placebo and did not adequately blind intervention [32]
and two studies reported a loss to follow up over the
course of the study of >25% [21,22]. Further, one study
did not report loss to follow up figures [33]. Performing a
sub-group analysis comparing these studies with theLai et al. BMC Public Health 2010, 10:331
http://www.biomedcentral.com/1471-2458/10/331
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higher quality studies showed no evidence of heterogene-
ity (χ2
1 = 0, p = 1). No significant variations were found
between results of studies randomising participants to:
<800 IU/day 1.14 (95%CI, 0.86-1.49) or ≥800 IU/day 1.12
(95%CI, 0.96-1.32); vitamin D2 1.21 (95%CI, 0.99-1.48) or
vitamin D3  1.06 (95%CI, 0.88-1.28); oral 1.08 (95%CI,
0.94-1.25) or intramuscular injections 1.49 (95%CI, 1.02-
2.18); placebo 1.11 (95%CI, 0.97-1.28) or no placebo 1.36
(95%CI, 0.80-2.34); reported levels of non-compliance
(≤15% 1.26 [95%CI, 1.03-1.55] vs >15% 1.03 [95%CI, 0.86-
1.24]); or between nursing home 1.11 (95%CI, 0.91-1.36)
and community residents 1.14 (95%CI, 0.95-1.37). There
was no evidence of publication bias.
Case-control studies
Vitamin D status
A total of 17 eligible studies of hip fracture and serum
25(OH)D levels were identified, including a total of 1903
hip fracture cases and 1953 control participants [34-50].
Eleven studies specified the time at which blood samples
were obtained and all but one gave the assay method used
to determine 25(OH)D concentration. The collection of
sera ranged from the point of admission to hospital up to
a maximum mean of 35 days post-fracture. The reported
average age in all studies for both cases and controls
ranged from 69 [48] to 84 years [49].
Of the 17 case-control studies, nine were population-
based [34-36,38-42,44] and eight were hospital-based
[37,43,45-50]. There was a strong relationship between
control type and year of publication. Eight of the nine
studies published in 1992 or earlier were population-
based case-control studies whilst seven of the remaining
eight studies published in 1995 or later were hospital-
based case-control studies.
Table 2 shows characteristics of the studies including
control populations, mean age, time of serum collection,
assay technique, and geometric mean serum 25(OH)D
and parathyroid hormone (PTH) levels. Figure 3 presents
a plot of the studies, stratified according to the source of
controls. There was no evidence of heterogeneity in rela-
tion to geographical location, mean age of controls, time
Figure 1 Study selection of randomised controlled trials.
175 Potentially relevant studies 
identified and screened for retrieval 
142 studies excluded 
(reviews, observational studies and non-randomised trials, 
no fracture outcomes, non-vitamin D supplementation) 
8 studies excluded 
(combined vitamin D treatments with calcium, too few 
participants or fractures) 
15 potentially appropriate for 
inclusion 
33 abstracts for assessment 
18 studies excluded  
(use of active vitamin D analogues, no specific hip fracture 
data) 
7 studies included in analysis L
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Table 1: Summary of identified randomised controlled trials
Study first author 
(country) year
Study 
population
Mean age 
(years)
Vitamin D Control Hip Fractures RR/HR
n Eqv daily dose and 
type
Mode of 
admin
25(OH)D 
Baseline nmol/L
n 25(OH)D 
Baseline nmol/L
Number 
Vit D/ Control
Vitamin D vs. Placebo/No treatment trials
Lips [29] 
(Netherlands) 1996
Community & 
limited care 
residents
80 1291 400 IU oral 27 1287 26 58/48 HR
D3 1.18 (0.81-1.71)
Meyer [30] (Norway) 
2002
Nursing home 
residents
84.7 569 400 IU oral 47 575 51 50/47 HR
D3 1.09 (0.73-1.63)
Trivedi [31] (UK) 2003 Community 
Doctors' and GP 
registry
74.8 1345 822 IU oral NA 1341 53.4 21/24 HR
D3 0.85 (0.47-1.53)
Grant [21] (UK) 2005 Community 
residents with 
previous 
fracture
77 1343 800 IU oral 38.0 1332 38.0 47/41 RR
D3 1.14 (0.75-1.72)
Law [32] (UK) 2006 Residential care 
and nursing 
home residents
85 1762 1100 IU oral 59 1955 NA 24/20 RR
D2 1.36 (0.80-2.34)L
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Lyons [22] (UK) 2007 Residential, 
nursing homes 
and sheltered 
housing 
residents
84 1725 822 IU oral NA 1715 NA 112/104 RR
D2 1.07 (0.83-1.39)
Smith [33] (UK) 2007 Community 
residents
79.1 4727 822 IU Intra-musc. (IM) 141.25 4713 141.25 66/44 HR
D2 1.49 (1.02-2.18)
Vitamin D and Calcium vs. Calcium trials
Grant [21] (UK) 2005 Community 
residents with 
previous 
fracture
77 1306 800 IU D3 + 1000 mg 
Calcium(daily)
oral 38.0 1311 38.0 46/49 RR
0.94 (0.63-1.40)
Eqv Equivalent
RR Relative risk
HR Hazard Ratio
IU International Units
Table 1: Summary of identified randomised controlled trials (Continued)Lai et al. BMC Public Health 2010, 10:331
http://www.biomedcentral.com/1471-2458/10/331
Page 7 of 17
between fracture and serum collection or type of vitamin
D assay.
Studies using population-based controls included 818
hip fracture cases and 837 controls. There was significant
heterogeneity (χ28 = 76.28, p < 0.001 and H = 3.09, I2 =
89.5%, p < 0.001) largely driven by three outlying studies
[34,36,44], however the direction of the difference was
consistent in all but one study. The weighted average of
log ratios showed around 40% (log ratio -0.51) lower
serum vitamin D levels in hip fracture cases compared
with population-based controls.
The hospital-based case-control studies included 1085
hip fracture cases and 1116 controls. In seven of the eight
studies, cases had significantly lower serum 25(OH)D
concentrations than controls. The combined log ratio
showed around 24% (log ratio -0.28) lower serum vitamin
D levels in hip fracture patients compared to hospital-
based controls with no significant heterogeneity (χ2
7 =
10.62, p = 0.156 and H = 1.23, I2 = 34.1%, p = 0.319). The
summary results for population-based and hospital-
based case-control studies differed significantly (χ2
1  =
51.02, p < 0.001).
Overall, in 15 of the 17 case-control studies hip fracture
patients had significantly lower 25(OH)D levels than con-
trols. A total combined estimate showed around 33% (log
ratio -0.40) lower 25(OH)D level in cases compared to
controls, although significant heterogeneity existed
between studies (χ2
16 = 137.9, p < 0.001 and H = 2.94, I2 =
88.4%, p < 0.001). This broad summary should therefore
be regarded with caution.
Seven studies were identified as lower quality studies
with a rating of either 1 [34,40] or 2 [38,41,42,46,48].
Comparing these studies with the higher quality studies
with ratings 3 [37,43,47,50], 4 [35,36,39,45], or 5 [44,49],
there were no signs of heterogeneity (χ2
1 = 0.14, p = 0.71).
There was no evidence of publication bias.
Parathyroid hormone
Ten eligible case-control studies of PTH and hip fracture
were identified. These were essentially a subset of studies
examining 25(OH)D [37,39,42-45,47-50]. Figure 4 pres-
ents the studies identified, including 905 hip fracture
Figure 2 HR/RR of hip fracture in randomised trials. Hazard Ratio/Relative Risk of hip fracture in individuals randomised to vitamin D supplemen-
tation compared to placebo/control in eligible randomised trials
0.5 1.0 1.5 2.0
Study Vitamin D
Fractures/
Subjects
Control
Fractures/
Subjects
Dose
(IU)*
HR/RR (95% CI)
Lips 1996 [29] 58/1291 48/1287 400 1.18 (0.81−1.71)
Meyer 2002 [30] 50/596 47/575 400 1.09 (0.73−1.63)
Trivedi 2003 [31] 21/1345 24/1341 820 0.85 (0.47−1.53)
Grant 2005 [21] 47/1343 41/1332 800 1.14 (0.75−1.72)
Vitamin D vs Placebo
Grant 2005 [21] 46/1306 49/1311 800 0.94 (0.63−1.40)
Vitamin D and Calcium vs Calcium
Law 2006 [32] 24/1762 20/1955 1100 1.36 (0.80−2.34)
Lyons 2007 [22] 112/1725 104/1715 820 1.07 (0.83−1.39)
Smith 2007 [33] 66/4727 44/4713 820 1.49 (1.02−2.18)
Total 424/14095 377/14229 1.13 (0.98−1.29) Total
Favours Vitamin D Favours Control
*Equivalent daily dose of vitamin D in international units
χ
2=4.44 df=7 p=0.73 for heterogeneityL
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Table 2: Characteristics of Hip fracture case-control studies
Study first author 
(location) year
Cases Controls Participant details
n Mean Age (SD) years 
25(OH)D (SD) nmol/L 
PTH (SD) pmol/L
Time sera 
collected 
(25(OH)D 
assay method)
n Mean Age (SD) years 
25(OH)D (SD) nmol/L 
PTH (SD) pmol/L
Population based controls
Lund [34] 67 NR On admission 41 NR Cases: Consecutive patients
(Denmark) 1975 65.0 (45.0) 
NR
(CPB) 55.0 (32.5) 
NR
Controls: Elderly participants without malabsorption, hepatic or renal disease
Baker [35] 98 80.2 (7.3) - 76 79.4 (7.2) Cases: Consecutive admissions of Caucasian females
(UK) 1979 34.5 (24.5) 
NR
55.8 (33.8) 
NR
Controls: Home-based age and sex matched selected from electoral register
Hoikka [36] 55 76.0 - 22 71.0 Cases: Patients admitted from Sept 1978- July 1979
(Finland) 1982 26.6 (18.5) 
NR
(HPLC) 56.4 (28.2) 
NR
Controls: Healthy age, sex and season matched
Morris [38] 67 77.9 - 50 71.5 Cases: Female hip fracture patients operated on by author
(Australia) 1984 39.2 (21.3) 
NR
(CPB) 67.6 (30.4) 
NR
Controls: Home-based, ambulant elderly females
Lips [39] 86 73.1 (11.5) - 74 75.6 (4.2) Cases: Hip fracture patients
(Netherlands) 1987 20.4 (11.5) (CPB after HPLC) 32.9 (13.6) Controls: Healthy, independent volunteers living in apartment house for elderly
0.11 (0.05)* 0.12 (0.05)*
Lau [40] 198 NR On day of 
admission 
368 NR Cases: Consecutive patients
(Hong Kong) 1989 45.5 (16.4) 
NR
(CPB) 73.8 (21.0) 
NR
Controls: Sheltered housing residentsL
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Pun [41] 69 78.1 (10.2) Within 12 h 
admission 
28 71.2 (6.4) Cases: Female hip fracture patients
(Hong Kong) 1990 43.7 (22.4) 
NR
(CPB) 54.6 (13.1) 
NR
Controls: Healthy female participants over 60 y
MacDonald [42] 61 78.9 (10.7) Within 24 h 
admission pre-
surgery 
61 78.6 (6.0) Cases: Unselected Chinese female patients admitted to orthopaedic ward
(Hong Kong) 1992 45.8 (22.0) (CPB) 72.5 (21.5) Controls: Hostel for elderly, no fracture history
4.59 (2.27) 4.04 (2.24)
Boonen [44] 117 79.2 (8.9) Within 18 h 
fracture pre-
surgery 
117 77.7 (5.4) Cases: Consecutive female patients
(Belgium) 1997 25.3 (22.0) (CPB) 53.8 (33.3) Controls: Female, age matched, from general practices
5.14 (4.66) 1.70 (1.14)
Community based controls
Von Knorring [37] 58 77.0 (9.3) Prior to surgery  41 78.0 (8.4) Cases: Patients admitted during 2 month periods in summer, winter and early 
spring
(Finland) 1982 32.4 (17.0) (CPB) 44.7 (22.5) Controls: Age and sex matched non-orthopaedic outpatients or minor surgery 
patients
0.45 (0.24)* 0.35 (0.24)*
Benhamou [43] 57 83.9 (5.9) Within 24 h 
admission 
68 82.5 (5.0) Cases: Consecutively admitted patients
(France) 1995 30.9 (12.2) (RIA) 38.4 (14.7) Controls: Patients in geriatric or rheumatology unit with no bone disease or 
fracture history
6.34 (4.65) 4.74 (2.21)
Thiebaud [45] 179 80.2 (9.6) 5-18 post 
fracture 
180 79.9 (9.6) Cases: Consecutive admissions of original hip fracture caused by fall from 
standing height or less
(France) 1997 23.5 (20.3) (Radio-
receptor)
30.6 (25.4) Controls: Age and sex matched emergency patients with no fracture history
3.32 (2.77) 4.62 (3.38)
Table 2: Characteristics of Hip fracture case-control studies (Continued)L
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Di Monaco [46] 444 79.7 (8.6) During hosp 
mean 35 days 
post fracture 
444 75.5 (5.7) Cases: Caucasian patients sustaining original hip fracture
(Italy) 2004 21.2 (19.5) (immuno-
enzymatic)
24.4 (21.7) Controls: Home-based elderly over 65 y referred for first osteodensiometry, no 
fracture history
6.02 (4.56) 5.28 (2.32)
Nuti [47] 74 77.4 (9.3) Within 24 h 
fracture 
73 71.2 (6.1) Cases: Self-sufficient, community-living female patients with adequate sunlight 
admitted between May-Dec 1999
(Italy) 2004 83.5 (55.0) (CPB) 107.3 (60.0) Controls: Metabolic disease unit outpatients with osteoporosis, no evident 
osteoporotic fractures admitted between Jul-Nov 1999. Otherwise as per cases
4.02 (1.79) 3.86 (1.43)
Bakhtiyarova [48] 63 68.8 (9.5) Within 3 days 
admission 
97 70.2 (8.3) Cases: Low trauma fracture patients
(Russia) 2006 22.4 (11.4) (CPB) 28.1 (10.1) Controls: Patients of ophthalmology unit with no fracture
3.7 (3.3) 4.9 (2.8)
Giusti [49] 160 84.0 (6.3) Within 24 h 
admission (RIA)
160 82.0 (7.6) Cases: Sampled patients admitted to Orthogeriatric unit between Nov 2004-Mar 
2005
(Italy) 2006 9.4 (11.6) 9.2 (9.1) Controls: Age, sex and place matched Acute Care unit patients admitted for non-
bone reasons
8.95 (7.79) 9.16 (8.00)
Sakuma [50] 50 82.6 (8.7) On admission  53 77.2 (5.3) Cases: Sado Island residents admitted to hospital from Jan-Dec 2004
(Japan) 2006 44.5 (19.4) (ELISA) 64.5 (18.5) Controls: Orthopaedic patients with no fracture admitted between Jul-Dec 2004
4.75 (2.34) 3.31 (1.93)
CPB: competitive protein binding
HPLC: high profile liquid chromatography
RIA: radioimmunoassay
ELISA: enzyme linked immunoassay
NR: not reported
* non-standardised units
Table 2: Characteristics of Hip fracture case-control studies (Continued)Lai et al. BMC Public Health 2010, 10:331
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cases and 924 controls from three population-based case-
control and seven hospital-based case-control studies.
Two of the studies showed significantly higher PTH levels
i n  h i p  f r a c t u r e  p a t i e n t s  c o m p a r e d  t o  c o n t r o l s  [ 4 4 , 5 0 ]
while two studies showed relationships in the opposite
direction with significantly lower PTH levels in the hip
fracture patients compared to controls [45,48]. The other
six studies showed no significant difference between case
and control groups. These results were not related to the
time between fracture and serum collection. There was
no evidence of publication bias.
There was significant and substantial heterogeneity
between study results within both the subgroups of popu-
lation-based case-control and hospital-based case-con-
trol studies. After combining the estimates, there was no
significant difference between the PTH levels in cases
and controls (difference in cases compared to controls
12%, log ratio 0.11) although substantial heterogeneity
was evident overall (χ2
9 = 149.68, p < 0.001, and H = 4.08,
I2 = 94%, p < 0.001) and this summary result should there-
fore be interpreted with caution. Two studies were identi-
fied as lower quality studies with a rating of 2 [42,48].
There were no signs of heterogeneity between studies
with lower, compared to higher (3 [37,43,47,50], 4 [39,45],
or 5 [44,49]), quality ratings (χ2
1 = 2.52, p = 0.112).
Cohort studies
Table 3 shows the three identified cohort studies investi-
gating 25(OH)D levels and hip fracture [51-53]. Two
studies used nested case-control designs. One of these
studies did not find a significant association between
serum 25(OH)D and hip fracture using a cut-off point of
47.5 nmol/L [51]. Another study containing 400 hip frac-
tures found a dose-related increase in hip fracture risk for
lower serum 25(OH)D levels (OR = 1.33 [95%CI, 1.06-
1.68] for each 25 nmol/l decrease) [52], while the third
study concluded that there was a significantly reduced
risk of hip fracture in those with 25(OH)D levels greater
than or equal to 62.5 nmol/L compared to levels below
this (RR = 0.64 [95%CI, 0.48-0.89]) [53]. For comparabil-
ity with the previous studies, the reciprocal of this value is
RR = 1.56 (95%CI, 1.12-2.08). Despite the differences in
Figure 3 25(OH)D in case-control studies. Ratio of serum 25(OH)D levels in hip fracture patients compared to controls in eligible case-control stud-
ies.
−1.0 −0.5 0.0 0.5
p = 0.001 for heterogeneity
p = 0.156 for heterogeneity
Study Cases/controls Log ratio of
Geometric mean
95% CI
Lund 1975 [34] 67/41  0.12 (−0.07, 0.31) Lund 1975 [34]
Baker 1979 [35] 98/76 −0.53 (−0.68,−0.37) Baker 1979 [35]
Hoikka 1982 [36] 55/22 −0.84 (−1.06,−0.62) Hoikka 1982 [36]
Morris 1984 [38] 67/50 −0.58 (−0.73,−0.44) Morris 1984 [38]
Lips 1987 [39] 86/74 −0.54 (−0.66,−0.41) Lips 1987 [39]
Lau 1989 [40] 198/368 −0.51 (−0.56,−0.46) Lau 1989 [40]
Pun 1990 [41] 69/28 −0.31 (−0.44,−0.18) Pun 1990 [41]
MacDonald 1992 [42] 61/61 −0.52 (−0.64,−0.40) MacDonald 1992 [42]
Boonen 1997 [44] 117/117 −0.88 (−1.05,−0.70) Boonen 1997 [44]
Population based controls 818/837 −0.51 (−0.64,−0.38)
Von Knorring 1982 [37] 58/41 −0.33 (−0.49,−0.17) Von Knorring 1982 [37]
Benhamou 1995 [43] 57/68 −0.22 (−0.34,−0.10) Benhamou 1995 [43]
Thiebaud 1997 [45] 179/180 −0.28 (−0.45,−0.11) Thiebaud 1997 [45]
Di Monaco 2004 [46] 444/444 −0.16 (−0.29,−0.04) Di Monaco 2004 [46]
Nuti 2004 [47] 74/73 −0.29 (−0.45,−0.14) Nuti 2004 [47]
Bakhtiyarova 2006 [48] 63/97 −0.28 (−0.40,−0.16) Bakhtiyarova 2006 [48]
Giusti 2006 [49] 160/160 −0.10 (−0.50, 0.30) Giusti 2006 [49]
Sakuma 2006 [50] 50/53 −0.42 (−0.54,−0.30) Sakuma 2006 [50]
Hospital based controls 1085/1116 −0.28 (−0.33,−0.23)
< 25(OH)D in cases > 25(OH)D in casesLai et al. BMC Public Health 2010, 10:331
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the cutoff points in serum 25(OH)D levels used in these
analyses, the results of the cohort studies are essentially
consistent with one another and qualitatively similar to
those of the case-control studies, with overlapping confi-
dence intervals and generally elevated risks of hip frac-
ture in those with lower 25(OH)D levels. It should be
noted that in the one study that permitted the compari-
son of mean 25(OH)D levels in cases and controls, the
difference appeared less extreme than that seen in the
case-control studies, although 25(OH)D levels were still
statistically different (cases 55.95 nmol/L [SD 20.28] vs.
controls 59.60 nmol/L [SD 18.20], p = 0.007).
Discussion
This meta-analysis shows no significant difference in the
risk of hip fracture between individuals randomised to
receive either vitamin D supplements or placebo/control.
In particular, no significant benefit for hip fracture was
shown in trials randomising participants to receive high
dose vitamin D (i.e. doses of 800 IU per day or greater). In
apparent contrast, case-control studies show substan-
tially and significantly lower serum 25(OH)D levels in
persons with hip fractures compared to controls.
Strengths and Weaknesses
A strength of this meta-analysis is the presentation of a
comprehensive collection of randomised controlled tri-
als, case-control studies and cohort studies, allowing a
broader comparison of published results than previously
considered. The effect of vitamin D supplementation was
separated from that of other medications in the RCT
data. Clearly defined methods were used in the selection
of the studies and analysis of the results to ensure validity
and consistency. Furthermore, this represents the first
summary of serological evidence on both vitamin D and
PTH in relation to hip fracture, and the first meta-analy-
sis of case-control studies on this topic. By placing the
evidence of the case-control studies alongside the results
of the randomised controlled trials we highlight the com-
plexity of the problem and the difficulty in drawing ade-
quate conclusions.
This study is constrained by the detail and quality of
published data of the respective studies included. Many
of the case-control studies were relatively small, con-
tained few hip fractures and reported highly variable
serum measurements. Individual participant data were
rarely published especially in larger studies, limiting a
more detailed analysis of patient characteristics. The sub-
stantial heterogeneity in the results of the population-
based case control studies of 25(OH)D and hip fracture,
and the studies of PTH levels mean that the summary
results should be considered as providing a broad indica-
tion of the overall direction of study findings, rather than
a precise estimate of the combined study results. Despite
Figure 4 PTH in case-control studies. Ratio of serum PTH levels in hip fracture patients compared to controls in eligible case-control studies.
−1.0 −0.5 0.0 0.5 1.0 1.5
p<0.0001 for heterogeneity
Study Cases/controls Log ratio of
Geometric mean
95% CI
Lips 1987 [39] 86/74 −0.10 (−0.39, 0.19) Lips 1987 [39]
MacDonald 1992 [42] 61/61 0.15 (0.00, 0.31) MacDonald 1992 [42]
Boonen 1997 [44] 117/117 0.99 (0.78, 1.20) Boonen 1997 [44]
Von Knorring 1982 [37] 58/41 0.32 (−0.04, 0.68) Von Knorring 1982 [37]
Benhamou 1995 [43] 57/68 0.17 (−0.01, 0.36) Benhamou 1995 [43]
Thiebaud 1997 [45] 179/180 −0.38 (−0.53,−0.23) Thiebaud 1997 [45]
Nuti 2004 [47] 74/73 0.01 (−0.10, 0.13) Nuti 2004 [47]
Bakhtiyarova 2006 [48] 63/97 −0.43 (−0.68,−0.19) Bakhtiyarova 2006 [48]
Giusti 2006 [49] 160/160 −0.02 (−0.21,0.17) Giusti 2006 [49]
Sakuma 2006 [50] 50/53 0.40 (0.23, 0.57) Sakuma 2006 [50]
All Studies 905/924 0.11 (−0.13,0.35)
< PTH in cases > PTH in casesLai et al. BMC Public Health 2010, 10:331
http://www.biomedcentral.com/1471-2458/10/331
Page 13 of 17
some studies being of lower quality, investigations
revealed no heterogeneity between results of higher and
lower quality studies, both for randomised controlled tri-
als and case-control studies.
Other potential limitations may include measurement
error in 25(OH)D levels from poor assay standardisation
[54], misclassification bias in hip fracture status or publi-
cation bias from the inclusion of smaller studies.
Other studies
There have been several meta-analyses of randomised
controlled trials published on this topic. A Cochrane
review showed similar results for hip fracture risk to the
present study with a summary RR of 1.15 (95%CI, 0.99-
1.33), in individuals randomised to receive vitamin D
compared to placebo or control [5]. A pooled analysis of
individual level randomised controlled trial data showed
a borderline statistically non-significant decrease in hip
fracture risk from vitamin D + calcium supplementation
and no reduction in risk from vitamin D supplementation
alone [55]. However, these reviews did not consider
results from observational studies or the role of PTH as
we have done here. Shrier et al suggest that the advan-
tages of including observational studies with RCTs in
meta-analyses may outweigh the disadvantages [18]. By
considering the evidence in its entirety we are able to
offer plausible hypotheses for the apparent null effect
seen in RCTs.
Several explanations have been previously proposed for
the null Randomised Controlled Trial results. A previous
meta-analysis of the relationship between vitamin D sup-
plementation and overall fracture risk stratified by dosage
concluded that supplementation of 700-800 IU/d is nec-
essary to reduce non-vertebral fractures [6]. This was fol-
lowed up most recently by the same authors with another
meta-analysis supporting the same conclusion of a dose-
dependence [7]. However, these studies did not assess the
impact of vitamin D alone but rather included combined
treatments with calcium, and calcium alone has been
shown to have a significant impact on fracture risk [12].
The latter meta-analysis of calcium treatment reported
that the addition of trials of vitamin D + calcium to cal-
cium-only trial results did not change the treatment
effect significantly. The RR (95%CI) for fractures at all
sites for calcium-only supplementation compared to pla-
cebo was 0.90 (95%CI, 0.80-1.00), which became 0.87
(95%CI, 0.77-0.97) when calcium + vitamin D versus pla-
cebo trial results were added; these RR did not differ sig-
nificantly from one another (p = 0.63). This highlights the
critical question of whether vitamin D supplementation is
itself effective, either with or without calcium supple-
mentation.
Explaining the inconsistent randomised and observational 
results
Where randomised and observational evidence are
inconsistent, it is generally most appropriate to place
more weight on the randomised evidence for clinical
decision making. Although the reason for the apparent
difference between the randomised and observational
evidence on vitamin D and hip fracture is not known,
there are a number of possible explanations, the most
obvious being that the results of the observational studies
may be affected by uncontrolled confounding. The risk of
hip fracture is increased by many factors such as advanc-
ing age, lack of physical activity, low body mass index,
Table 3: Characteristics of cohort studies
Study First 
author 
(country) year
n Follow up time Study population 
Mean age years
Hip 
Fractures
Findings
Study of 
Osteoporotic 
Fractures
9704 Up to 5.9 years Postmenopausal women 332 < 47.5 nmol/L vs. ≥47.5 nmol/L 25(OH)D
Cummings [51] 
(USA) 1998
73 years (using randomly 
selected cases and 
controls)
RR Hip fracture 1.2 (0.7, 1.9)
WHI-OS 39793 Up to 9.3 years Postmenopausal women 400 Each 25 nmol/L decrease in 25(OH)D R Hip fracture 
1.33 (1.06, 1.68)
Cauley [52] 
(USA) 2008
(median 7.1 years) 71 years ≤47.5 nmol/L vs. ≥70.7 nmol/L OR Hip fracture 1.71 
(1.05, 2.79)
NHANES III 1917 Mean 6.7 y ≥65 y Caucasian adults 156 ≥62.5 nmol/L vs. <62.5 nmol/L 25(OH)D
Looker [53] 
(USA) 2008
73 years RR Hip fracture 0.64 (0.46, 0.89)Lai et al. BMC Public Health 2010, 10:331
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smoking, co-morbidities and frailty. Many of these fac-
tors are also likely to reduce exposure to sunlight and
therefore vitamin D levels. Since only six of the case-con-
trol studies summarised here accounted for age and none
adjusted for current illness or disability, it seems likely
that the results of the observational studies may be sub-
ject to residual confounding. T his is support ed by our
finding of a greater difference in 25(OH)D levels in case-
control studies using population rather than hospital con-
trols. Previous studies suggest hospital patients and nurs-
ing home residents may have frailty patterns more
comparable to hip fracture patients and have lower
25(OH)D levels compared to independent elderly partici-
pants [56] who are likely more ambulant and healthier.
One of the cohort studies did attempt to adjust for frailty
and physical functioning [52] and these factors were
found to attenuate the association between low serum
vitamin D status and hip fracture risk, although it
remained marginally statistically significant. Further sim-
ilar investigations are necessary to better quantify the
likely impact of such confounding and may help explain
these conflicting results.
A second explanation is that vitamin D is indeed bene-
ficial and the randomised controlled trials may not have
been able to detect this effect. There may have been inad-
equate power in the trials because of limited follow up
and the relatively small number of recorded hip fractures.
However the results of a Cochrane review of all fracture
sites (summary RR = 1.01 [95%CI, 0.93-1.09]), including
more events with greater statistical power, and vertebral
fractures only (RR = 0.90 [95%CI, 0.42-1.92]) were similar
to those reported here, in individuals randomised to
receive vitamin D compared to placebo or control [5].
Performing the analysis on an intention-to-treat basis is
consistent with recommendations [57] although it may
obscure the effect of poor adherence to treatment or fol-
low up that may reduce the observed treatment effect.
However, not all studies reported detailed information on
adherence rates and of those that did, four estimated the
proportion of adherent participants greater than 75%
[22,29-31], and only one study reported lower adherence
to treatment of around 50% [21]. This latter study
reported a similar treatment effect compared to other
studies where there was better adherence.
Another proposed explanation for the different findings
of RCTs and observational studies, in particular the lack
of a significant treatment effect in the RCTs, is that the
doses of vitamin D used in many of the studies may have
been too low to achieve hip fracture reduction. Some
studies suggest that a minimum supplementation of 700-
800 IU/d is necessary to reduce non-vertebral fractures
[6]. However as already noted, the treatment effect of tri-
als within this dosage range were not found to differ sig-
nificantly from those in lower dose trials in the present
meta-analysis. Furthermore, the doses of vitamin D sup-
plementation used in both high and low dose randomised
controlled trials resulted in increases in serum 25(OH)D
levels that were similar to, or in excess of, the differences
between cases and controls in the observational data
[21,29,30,32,33]. This suggests that the apparent discrep-
ancies between the observational and randomised data
are unlikely to be explained by dose alone; it remains pos-
sible, though currently unsupported, that very high doses
of vitamin D could prevent fracture.
F i n a l l y ,  i t  is  po s s i b l e  t h a t  s o m e  o t h e r  fa ct o r ,  s u c h  as
exposure to sunlight or genotypic factors, independently
reduces hip fracture risk and is related to increased
serum 25(OH)D levels, but is not simulated by vitamin D
supplementation.
PTH and hip fracture
There was no significant difference between PTH levels
in hip fracture cases and controls. Low 25(OH)D levels
lead to a small decrease in serum 1,25(OH)2D and cal-
cium absorption that in turn stimulates the secretion of
PTH to maintain adequate 1,25(OH)2D production and
calcium homeostasis [56]. This secondary hyperparathy-
roidism leads to increased bone turnover, bone loss and
possibly increased hip fracture risk. It might be expected
then that hip fracture patients compared to controls
would have elevated PTH measurements consistent with
lower 25(OH)D levels. This was not evident although
there was significant heterogeneity between studies.
The heterogeneity was not attributable to the timing of
sera collection or stratification by population-based or
hospital-based controls. However, PTH can vary signifi-
cantly over a short period and the impact on serum mea-
surements from fracture and subsequent trauma is not
well understood. One study showed elevated PTH levels
immediately after hip fracture that fell significantly two
weeks later [58], while others have reported serum levels
increasing [59] or remaining stable [60] during hip frac-
ture recovery. Comparatively, 25(OH)D has a much lon-
ger half-life in circulation and studies have consistently
showed no changes in 25(OH)D levels from post-fracture
through to recovery [58,61].
Implications and future research
Despite the null findings from the randomised controlled
trials, vitamin D is widely recommended and used with
the aim of preventing fracture. Current guidelines for
bone health support both vitamin D supplementation
only, starting from as little as 400 IU/day for individuals
who may be sunlight deprived [1], and combined vitamin
D and calcium supplementation, as part of broader osteo-
porosis treatment [3]. However despite current practice,
the question still remains of whether vitamin D itself is
actually effective. There is insufficient evidence at presentLai et al. BMC Public Health 2010, 10:331
http://www.biomedcentral.com/1471-2458/10/331
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to support widespread vitamin D supplementation for
fracture prevention. In particular, lack of consistency
within the epidemiological evidence highlights the possi-
ble impact of bias and confounding, as well as uncertain-
ties on dosage and therapy requirements.
The issue of confounding between vitamin D, physical
activity and comorbidity has implications beyond the
investigation of vitamin D and fracture. Physical activity,
and related body mass index, influences the risk of a wide
range of conditions and frailty and co-morbidity have
profound impacts on survival. Recently, low vitamin D
has been suggested as a risk factor for a number of condi-
tions, including prostate cancer [62], breast cancer
[63,64], type 1 and 2 diabetes [65], hypertension [66],
multiple sclerosis [67,68] and is speculated to reduce sur-
vival from melanoma [69]. These types of observations
are potentially affected by similar issues to those outlined
here and high quality evidence, ensuring that potential
confounding factors have been properly taken into
account, is required before definitive conclusions can be
reached regarding the effects of vitamin D. It should also
be borne in mind that a number of previous observational
studies showed reduced rates of cancer and other dis-
eases in individuals taking supplements such as beta-car-
otene, vitamin A and vitamin E [70]. Subsequent
randomised controlled trials revealed that these supple-
ments did not significantly prevent disease [71] and in the
case of beta-carotene led to an increased risk of cancer
and cardiovascular disease in smokers [72,73].
The way forward for fracture should focus upon
strengthening the evidence, informed by the results of
previous studies. Specifically, observational studies with
tighter control for confounding are likely to be informa-
tive. Randomised controlled trials using larger vitamin D
doses and combined vitamin D and calcium therapies
(versus calcium alone), with appropriate control groups
may also contribute to our understanding. Studies should
account appropriately for factors such as age, physical
activity, functional capacity and appropriate lifestyle fac-
tors when assessing the relationship between vitamin D
status and hip fracture. Genetic studies examining factors
relating to 25(OH)D levels may also provide useful
insights for future research [74-76].
Conclusions
A summary of the best available evidence shows that nei-
ther higher nor lower dose vitamin D supplementation
prevents hip fracture. Randomised and observational
findings on vitamin D and hip fracture appear to differ.
The reason for this is unclear; one possible explanation is
uncontrolled confounding in observational studies.
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